Abstract
Phosphatidylinositol 3-kinase (PI3K), a heterodimeric lipid kinase, is a key enzyme in signal transduction from various stimuli to downstream pathways that elicit diverse responses involving growth, proliferation, survival, differentiation, and metabolism in many cellular systems. Activated PI3K generates phosphatidylinositol-3,4,5-triphosphate, which recruits phosphatidylinositol-dependent kinase 1 (PDK1) and Akt serine/threonine kinase at the plasma membrane, resulting in activation of Akt. In turn, Akt activates multiple downstream targets, most notably the mTOR pathway. There is abundant evidence implicating the PI3K/Akt/mTOR pathway in the development and progression of a variety of tumors including hematologic neoplasms. Therefore, this pathway is considered a critical target for cancer therapy. We review the regulatory mechanisms of the PI3K/Akt/mTOR signaling pathway and the role of this pathway in oncogenesis of hematological malignancies.
Keywords: PI3K, Akt, mTOR, hematologic malignancies
Anti-Cancer Agents in Medicinal Chemistry
Title: Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies
Volume: 9 Issue: 9
Author(s): Kiyotaka Kawauchi, Toshie Ogasawara, Masako Yasuyama, Kuniaki Otsuka and Osamu Yamada
Affiliation:
Keywords: PI3K, Akt, mTOR, hematologic malignancies
Abstract: Phosphatidylinositol 3-kinase (PI3K), a heterodimeric lipid kinase, is a key enzyme in signal transduction from various stimuli to downstream pathways that elicit diverse responses involving growth, proliferation, survival, differentiation, and metabolism in many cellular systems. Activated PI3K generates phosphatidylinositol-3,4,5-triphosphate, which recruits phosphatidylinositol-dependent kinase 1 (PDK1) and Akt serine/threonine kinase at the plasma membrane, resulting in activation of Akt. In turn, Akt activates multiple downstream targets, most notably the mTOR pathway. There is abundant evidence implicating the PI3K/Akt/mTOR pathway in the development and progression of a variety of tumors including hematologic neoplasms. Therefore, this pathway is considered a critical target for cancer therapy. We review the regulatory mechanisms of the PI3K/Akt/mTOR signaling pathway and the role of this pathway in oncogenesis of hematological malignancies.
Export Options
About this article
Cite this article as:
Kawauchi Kiyotaka, Ogasawara Toshie, Yasuyama Masako, Otsuka Kuniaki and Yamada Osamu, Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/187152009789377772
DOI https://dx.doi.org/10.2174/187152009789377772 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas
Current Neuropharmacology Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Mining the Adenovirus "Virome" for Systemic Oncolytics
Current Pharmaceutical Biotechnology Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Current Cancer Therapy Reviews How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews Transplantation and Other Uses of Human Umbilical Cord Blood and Stem Cells
Current Pharmaceutical Design Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Imaging Studies in Hypercalcemia
Current Medicinal Chemistry New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer
Current Drug Targets Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials
Anti-Cancer Agents in Medicinal Chemistry Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Current Enzyme Inhibition